MX2019008911A - Metodos, matrices y usos de estos. - Google Patents

Metodos, matrices y usos de estos.

Info

Publication number
MX2019008911A
MX2019008911A MX2019008911A MX2019008911A MX2019008911A MX 2019008911 A MX2019008911 A MX 2019008911A MX 2019008911 A MX2019008911 A MX 2019008911A MX 2019008911 A MX2019008911 A MX 2019008911A MX 2019008911 A MX2019008911 A MX 2019008911A
Authority
MX
Mexico
Prior art keywords
pancreatic cancer
methods
determining
test sample
associated disease
Prior art date
Application number
MX2019008911A
Other languages
English (en)
Spanish (es)
Inventor
Borrebaeck Carl
Wingren Christer
Dexlin Mellby Linda
Nyberg Andreas
Original Assignee
Immunovia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovia Ab filed Critical Immunovia Ab
Publication of MX2019008911A publication Critical patent/MX2019008911A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MX2019008911A 2017-01-31 2018-01-31 Metodos, matrices y usos de estos. MX2019008911A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1701572.8A GB201701572D0 (en) 2017-01-31 2017-01-31 Methods, arrays and uses thereof
PCT/EP2018/052423 WO2018141804A1 (en) 2017-01-31 2018-01-31 Methods, arrays and uses thereof

Publications (1)

Publication Number Publication Date
MX2019008911A true MX2019008911A (es) 2019-09-26

Family

ID=58462729

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008911A MX2019008911A (es) 2017-01-31 2018-01-31 Metodos, matrices y usos de estos.

Country Status (13)

Country Link
US (1) US20190382849A1 (enExample)
EP (1) EP3577464A1 (enExample)
JP (1) JP2020507760A (enExample)
KR (1) KR20190109422A (enExample)
CN (1) CN110325860A (enExample)
AU (1) AU2018214180A1 (enExample)
BR (1) BR112019015633A2 (enExample)
CA (1) CA3051968A1 (enExample)
GB (1) GB201701572D0 (enExample)
IL (1) IL268244A (enExample)
MX (1) MX2019008911A (enExample)
RU (1) RU2019123695A (enExample)
WO (1) WO2018141804A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008117067A2 (en) 2007-03-27 2008-10-02 Carl Arne Krister Borrebaeck Protein signature/markers for the detection of adenocarcinoma
CA3142634A1 (en) * 2019-07-03 2021-01-07 Crystal Bioscience Inc. Anti-b7-h3 antibody and methods of use thereof
KR102289278B1 (ko) * 2019-07-09 2021-08-13 주식회사 베르티스 췌장암 진단용 바이오마커 패널 및 그 용도
JP2023507369A (ja) * 2019-12-20 2023-02-22 メディミューン，エルエルシー グリピカン３を標的とするキメラ抗原受容体を用いて癌を治療する組成物及び方法
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
AU2022244125A1 (en) * 2021-03-26 2023-10-19 BioNTech SE Combination therapy with an anti-ca19-9 antibody and folfirinox in the treatment of cancer
CN113336851B (zh) * 2021-06-30 2021-12-24 徐州医科大学 新型全人源抗人b7h3抗体、包含所述抗体的组合物及其应用
CN120177800B (zh) * 2025-05-23 2025-10-10 四川大学 血液生物标志物cfp在制备急性胰腺炎诊断试剂的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US8632983B2 (en) * 2005-04-15 2014-01-21 Van Andel Research Institute Biomarkers for pancreatic cancer and diagnostic methods
WO2008117067A2 (en) 2007-03-27 2008-10-02 Carl Arne Krister Borrebaeck Protein signature/markers for the detection of adenocarcinoma
WO2012031374A1 (zh) * 2010-09-09 2012-03-15 北京同为时代生物技术有限公司 用于诊断上皮源性癌症的血液标志物及其单克隆抗体
GB201103726D0 (en) 2011-03-04 2011-04-20 Immunovia Ab Method, array and use thereof
GB201206323D0 (en) * 2012-04-10 2012-05-23 Immunovia Ab Methods and arrays for use in the same
GB201319878D0 (en) * 2013-11-11 2013-12-25 Immunovia Ab Method, Array and use thereof
GB201516801D0 (en) * 2015-09-22 2015-11-04 Immunovia Ab Method, array and use thereof

Also Published As

Publication number Publication date
US20190382849A1 (en) 2019-12-19
BR112019015633A2 (pt) 2020-03-17
JP2020507760A (ja) 2020-03-12
KR20190109422A (ko) 2019-09-25
AU2018214180A1 (en) 2019-08-08
CA3051968A1 (en) 2018-08-09
IL268244A (en) 2019-09-26
GB201701572D0 (en) 2017-03-15
EP3577464A1 (en) 2019-12-11
CN110325860A (zh) 2019-10-11
RU2019123695A (ru) 2021-03-02
WO2018141804A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
MX2018013621A (es) Metodo, matriz y uso de estos.
MX2019008911A (es) Metodos, matrices y usos de estos.
WO2017050939A3 (en) Method and array for diagnosing pancreatic cancer in an individual
MX363201B (es) Procedimiento, matriz y uso para determinar la presencia de cancer pancreatico.
MX2016006125A (es) Procedimiento, matriz y uso de los mismos.
EP3839510A3 (en) Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
MX373248B (es) Prediccion de riesgo de evento cardiovascular y usos del mismo.
MY188938A (en) Therapeutic, diagnostic and prognostic methods for cancer of the bladder
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
AR095363A1 (es) Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
BR112016019836A2 (pt) método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito
WO2015094996A3 (en) Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
WO2015189591A3 (en) Method and arrays for use in diagnosing early breast cancer
GB201207297D0 (en) Analytical methods and arrays for use in the same
GB201014837D0 (en) Biomarker signatures and uses thereof
CL2017001972A1 (es) Biomarcadores para cáncer pancreático
MX2015013993A (es) Procedimientos y series para su uso en los mismos.
WO2014162008A3 (en) Biomarker signatures for predicting drug response in hodkin's lymphoma
WO2016198833A3 (en) Methods for analysing a urine sample
WO2016091888A3 (en) Methods, kits and compositions for phenotyping pancreatic ductal adenocarcinoma behaviour by transcriptomics
BR112016013976A2 (pt) método para determinar se um indivíduo é afetado por um câncer, método para discriminar entre câncer colorretal e pancreático dentre indivíduos que resultam ser positivos para o método, método para determinar o estágio de um câncer colorretal em um indivíduo afetado e uso de um kit de rt-pcr quantitativo para performar o método
BR112017006315A2 (pt) agente terapêutico, uso de um agente terapêutico, métodos in vitro para determinar se um sujeito com melanoma tem um risco maior de desenvolver metástase, de determinação de um regime de tratamento para um sujeito que sofre de melanoma, de tratamento de um sujeito que sofre de melanoma, ensaio in vitro para predizer o risco aumentado de metástase e kits
GB201206323D0 (en) Methods and arrays for use in the same
BR112018069279A2 (pt) métodos analíticos e matrizes para uso no mesmo
BR112017011026A2 (pt) métodos analíticos e arranjos para uso nos mesmos